U.S. FDA panel recommends approval of Johnson & Johnson's depression drug

An advisory panel to the U.S. Food and Drug Administration on Tuesday recommended Johnson & Johnson's experimental nasal spray, which has a compound similar to often-abused ketamine, for patients suffering from depression.